Enveric Biosciences

Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders.

: 375
: Public company
: 1994
: Cambridge, MA, USUnited States

Library

enveric.comCrawled Oct 15, 2026

Press

1 page

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit/news/enveric-biosciences-announces-participation-in-b-riley-securities-mind-muscle-vision-summit
Enveric Biosciences advances neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. It announced participation in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston.

Team

1 page

Team/team

About

1 page

Company/about

Contact

1 page

Contact/contact

Homepage

1 page

Homepage/

Privacy

1 page

Coverage

6 items

Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies – Enveric Biosciencesenveric.com/news/enveric-biosciences-announces-positive-results-from-recently-completed-ind-enabling-admet-studies/
Enveric Biosciences reports positive results from its IND-enabling ADMET studies, showing favorable oral absorption and systemic bioavailability in vitro. The findings support the company’s drug development pipeline by validating key pharmacokinetic properties. These studies are critical for advancing candidates toward Investigational New Drug (IND) applications.
Oct 2026enveric.comNews article
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series – Enveric Biosciencesenveric.com/news/enveric-biosciences-secures-new-u-s-patent-allowance-for-next-generation-non-hallucinogenic-mescaline-derivatives-in-evm401-series/
Enveric Biosciences obtains a U.S. patent for novel methylone-inspired compounds in its EVM401 series, designed as non-hallucinogenic derivatives for potential PTSD and psychiatric disorder treatments. The patent covers neuroplastogenic compounds aimed at addressing unmet medical needs in mental health. Claims focus on next-generation chemical structures distinct from traditional mescaline-based approaches.
Sep 2026enveric.comNews article
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 – Enveric Biosciencesenveric.com/news/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-second-quarter-2026/
Enveric Biosciences releases its second-quarter 2026 financial results, detailing revenue, expenses, and key operational metrics. The company provides an update on its pipeline, including progress in clinical-stage programs targeting autoimmune and inflammatory diseases. Leadership highlights strategic initiatives in business development and partnerships to advance therapeutic candidates.
Aug 2026enveric.comNews article
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 – Enveric Biosciencesenveric.com/news/enveric-biosciences-reports-new-preclinical-data-supporting-the-non-hallucinogenic-profile-of-lead-candidate-eb-003/
Enveric Biosciences presents new preclinical data showing its lead compound **EB-003** maintains a non-hallucinogenic profile. The findings from a **GloSensor™ assay** reinforce prior **BRET assay** results, supporting its progression toward **Phase 1 clinical trials**. The data align with the company’s focus on developing psychedelic-derived therapies without psychoactive side effects.
Aug 2026enveric.comNews article